Airdoc
Airdoc is a Beijing-based, HKEX-listed AI medical technology company developing retinal imaging AI for clinical screening and a consumer photobiomodulation device for pediatric myopia management, serving Chinese families and clinical screening markets including the EU.
- Company typePrivate
- Founded2015
- HeadquartersBeijing, China
- Headcount101–250
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Airdoc does
Airdoc is a Beijing-based, Hong Kong Stock Exchange-listed (hkg:02251) AI medical technology company founded in 2015 that develops retinal imaging artificial intelligence and consumer medical devices for eye health. Its core offerings span the PBM(R) Vision Rehabilitation Device — a photobiomodulation hardware product for home-based myopia management in children, priced at ¥13,800 as a one-time purchase — alongside AI-based systems for diabetic retinopathy screening (CE-certified in the EU as of October 2025), AI-driven chronic disease risk assessment using retinal biomarkers, AI anti-stress monitoring, and an AI Medical Large Model foundation model for healthcare. The underlying technology stack combines computer vision on fundus/retinal images, predictive analytics on biometric and health data, and a medical foundation model, with the PBM device adding AI-controlled low-intensity light therapy protocols.
The company operates through three branded business segments — Airdoc Medical (鹰瞳医疗), Airdoc Health (鹰瞳健康), and Airdoc Eye Health (鹰瞳眼健康) — and reaches customers primarily through direct-to-consumer e-commerce at airdoc.com for the PBM device, with clinical AI screening systems deployed to healthcare providers (including in the EU). Marketing relies on WeChat, Weibo, LinkedIn, and earned media coverage from CCTV's 'Foreseeing the World' program and the Beijing Medical Health Science and Technology Promotion Center. The company reports 100,000+ cumulative parent users of the PBM device, 13,000+ verified families, and a 90% parent satisfaction rate. Earlier funding rounds (2018-2019) brought in strategic investors including CITIC Group, Ping An Global Voyager, Fosun International, and Sogou.
Airdoc is led by founder & CEO Ray Zhang, with HE Chao as CTO and Bill Huang as a director, and operates with approximately 101-250 employees. The provided financial dataset contains unit inconsistencies (figures in the trillions) and is treated as unreliable; the company exhibits operating losses and negative EBITDA across 2021-2025 per that data, which is directionally consistent with a public, growth-stage medtech still investing in clinical validation, regulatory clearance, and consumer market development. The 2021 HKEX listing and October 2025 CE certification together represent the two largest structural capital and regulatory milestones underpinning the current scale-up.
Airdoc firmographics
Firmographics- Name
- Airdoc
- Legal name
- 北京鹰瞳科技发展股份有限公司
- Website
- https://airdoc.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Airdoc is a Beijing-based, HKEX-listed AI medical technology company developing retinal imaging AI for clinical screening and a consumer photobiomodulation device for pediatric myopia management, serving Chinese families and clinical screening markets including the EU.
- Ownership category
- akta.pro rank
Airdoc industry classification
Industry- Product category
- AI Medical Devices
- NAICS
- Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Ophthalmic Goods Manufacturing (339115)
- SIC
- Ophthalmic Goods (3851), Search, Detection, Navagation, Guidance, Aeronautical Sys (3812)
- akta.pro primary industry
- Pulmonary Function Testing (PFT) & Spirometry Equipment (HLAHAGAH)
- akta.pro secondary industry
- Avionics Displays & Human-Machine Interface (EFIS/HUD/HMD) (IMABAFAH)
Keywords
Where Airdoc is headquartered
LocationHeadquarters
- HQ city
- Beijing
- HQ country
- China
- HQ region
- Asia
Markets served
Airdoc business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations
Revenue model
- Hardware Product Sales: Revenue generated from direct sales of the PBM Vision Rehabilitation Device to consumers. The product is sold as a one-time purchase at ¥13,800, positioned as a consumer health device for home myopia management in children.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | PBM Vision Rehabilitation Device - Single SKU |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Airdoc product offering
Product offeringCore offering
Airdoc is a Beijing-based AI medical technology company that develops and sells retinal imaging artificial intelligence products. Its flagship commercial offering is the PBM(R) Vision Rehabilitation Device, a consumer home-use device using photobiomodulation (low-intensity light therapy) to slow myopia progression in children. The company also offers AI-based screening systems for diabetic retinopathy, chronic disease risk assessment, stress monitoring, and a medical large language model.
Product overview
Airdoc is a retinal imaging AI company offering a platform of AI-powered medical devices and systems. The core product portfolio includes the PBM(R) Vision Rehabilitation Device for myopia control, combined with AI diagnostic systems for chronic disease risk assessment and medical imaging analysis. The company operates across three main segments: Airdoc Medical (鹰瞳医疗), Airdoc Health (鹰瞳健康), and Airdoc Eye Health (鹰瞳眼健康), providing AI solutions for retinal screening, home-based myopia management, and general health monitoring.
Differentiator
Problem solved
Functional benefit
Products and services
- PBM(R) Vision Rehabilitation Device (鹰瞳PBM视觉功能改善系统) A consumer home-use medical device using photobiomodulation (PBM) low-intensity light therapy to slow myopia progression in children. Each session is 3 minutes, used twice daily with a 4-hour interval. Marketed directly to parents of myopic children for at-home eye care management.
- AI Diabetic Retinopathy Screening Systems AI systems for autonomous or semi-autonomous diabetic retinopathy screening that analyze fundus/retinal images to detect signs of diabetic retinopathy. CE-certified for the European Union market as of October 2025. Designed for clinical and healthcare provider use.
- AI Chronic Disease Risk Assessment (AI慢病风险评估) AI-powered risk assessment system that uses machine learning models to predict the risk of chronic diseases based on retinal imaging and other health data inputs.
- AI Stress Monitoring (AI抗压监测) AI-based stress monitoring and management system leveraging biometric and physiological signals.
Quantifiable outcome
- 90% parent satisfaction rate among users
- +1 more outcomes
Companies that use Airdoc
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Airdoc technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature2 records
Airdoc partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights6 records
Airdoc competitors and assessment
Company assessmentMarket position
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Airdoc social profiles
Digital presenceAirdoc financial estimates
Financial estimateRevenue estimate
Valuation estimate
Airdoc leadership team
Management profileNumber of profiles
Profiles3 records
Airdoc funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Airdoc M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Airdoc
What does Airdoc do?
Airdoc is a Beijing-based AI medical technology company that develops and sells retinal imaging artificial intelligence products. Its flagship commercial offering is the PBM(R) Vision Rehabilitation Device, a consumer home-use device using photobiomodulation (low-intensity light therapy) to slow myopia progression in children. The company also offers AI-based screening systems for diabetic retinopathy, chronic disease risk assessment, stress monitoring, and a medical large language model.
Is Airdoc a public or private company?
Airdoc is a private company. It is classified as public and is currently operating.
When was Airdoc founded?
Airdoc was founded in 2015. It employs 101 to 250 people.
Where is Airdoc based?
Airdoc is headquartered in Beijing, China, in the Asia region.
How does Airdoc make money?
One revenue line is on record: hardware Product Sales.
Does Airdoc have an API?
No public API is recorded for Airdoc.
What industry is Airdoc in?
Airdoc's product category is AI Medical Devices. Its primary akta.pro industry code is HLAHAGAH, Pulmonary Function Testing (PFT) & Spirometry Equipment, with a secondary code of IMABAFAH, Avionics Displays & Human-Machine Interface (EFIS/HUD/HMD). Its NAICS code is 33451 and its SIC code is 3851.